We describe the gene dosage-dependent compromised the ability of Smarca5-depleted MEFs to undergo these processes, in conjunction with deregulation of corresponding gene regulatory programs, thus directly implicating this important chromatin remodeler as a key determinant for cell fate decisions associated with early stages of cell transformation and initiation of cancer development. The gene discussed is SMARCA5; the disease is cancer.